Copper Drug Cuts Alzheimer's Plaques 42% in Lab Study

Scientists at Monash University just discovered a copper compound that helps brains clean out the toxic proteins that cause Alzheimer's. In lab studies, the drug reduced harmful buildup by 42% and boosted memory by nearly 44%.

The treatment works by fixing the brain's natural waste removal system. Think of it like unclogging a drain that's been blocked for years.

In healthy brains, tiny pumps called P-glycoproteins work at the blood-brain barrier to sweep out toxic amyloid-beta proteins before they can cause damage. In people with Alzheimer's, these pumps slow down dramatically, allowing harmful proteins to pile up and destroy memory.

The copper drug Cu(ATSM) increased the number of working pumps by 24%. Over 56 days, lab models showed significant improvement in both protein clearance and spatial learning.

Dr. Jae Pyun, the study's lead author, said this is the first time researchers have directly linked repairing the blood-brain barrier to measurable cognitive benefits. The drug essentially helps the brain do what it's supposed to do naturally.

Why This Inspires

What makes this discovery particularly exciting is that Cu(ATSM) has already been safety-tested in humans for Parkinson's disease and ALS. That means it could move into Alzheimer's trials much faster than a brand new drug starting from scratch.

Professor Joseph Nicolazzo, who directed the research, explained that because reducing amyloid is clinically proven to improve outcomes, these lab results strongly support testing the drug in people with early Alzheimer's symptoms.

The timing couldn't be more urgent. Dementia recently became Australia's leading cause of death, surpassing heart disease. Globally, millions of families are desperately waiting for treatments that can slow or prevent cognitive decline.

Researchers believe the drug may work in multiple ways beyond just fixing the pumps. They suspect it might also help the brain's immune cells break down existing toxic plaques, essentially attacking the problem from two angles.

The team published their findings in ACS Chemical Neuroscience and will continue studying exactly how the proteins move from brain to bloodstream once the barrier is repaired.

For the 55 million people worldwide living with dementia, this research offers something precious: a scientifically grounded reason to hope.